Low arugula surface free energy enhanced platinum nanoparticle adsorption, with decreased uptake and translocation to roots relative to escarole.

Agricultural food crop plants interact with engineered nanomaterials (ENMs) from the application of agri-food nanotechnologies and from unintentional emissions originating from other nanotechnologies. Both types of exposure present implications for agricultural yield and quality, food chain transfer, and environmental and human health. In this review, the most recent findings from agricultural plant-ENM studies published in 2017 and 2018 are summarized. The aim of this is to identify the current hazard potential of ENMs for plants grown under typical field conditions that originate from both intentional and unintentional exposures and to contribute to knowledge-based decisions on the application of ENMs in food-agriculture. We also address recent knowledge on ENM adsorption, internalization, translocation, and bioaccumulation by plants, ENM impacts on agricultural crop yield and nutrition, and ENM biotransformation. Using adverse effect level concentrations and data on ENM accumulation in environmental matrices, the literature analyses revealed that C-, Ag-, Ce-, and Ti-based ENMs are unlikely to pose a risk to plants grown under typical field conditions, whereas Cu- and Zn-based ENMs require surveillance. Since multiple factors (e.g., ENM concentration, route of exposure, and plant type) influence the effects of ENMs on plants, biomonitoring is recommended for tracking ENM environmental exposure in the future.

No abstract

Difficulties in obtaining and maintaining the desired level of the critical quality attributes (CQAs) of therapeutic proteins as well as the pace of the development are major challenges of current biopharmaceutical development. Therapeutic proteins, both innovative and biosimilars, are mostly glycosylated. Glycans directly influence the stability, potency, plasma half-life, immunogenicity, and effector functions of the therapeutic. Hence, glycosylation is widely recognized as a process-dependent CQA of therapeutic glycoproteins. Due to the typically high heterogeneity of glycoforms attached to the proteins, control of glycosylation represents one of the most challenging aspects of biopharmaceutical development. Here, we explored a new glycoengineering approach in therapeutic glycoproteins development, which enabled us to achieve the targeted glycoprofile of the Fc-fusion protein in a fast manner. Coupling CRISPRi technology with lectin-FACS sorting enabled downregulation of the endogenous gene involved in fucosylation and further enrichment of CHO cells producing Fc-fusion proteins with reduced fucosylation levels. Enrichment of cells with targeted glycoprofile can lead to time-optimized clone screening and speed up cell line development. Moreover, the presented approach allows isolation of clones with varying levels of fucosylation, which makes it applicable to a broad range of glycoproteins differing in target fucosylation level.